茶中的潜在毒性元素的综合评估:使用多模式统计的生物可用性,生物可访问性和健康风险分析
Riddhi Basu1, Saibal Ghosh1,2, Gourav Mondal1
1Agricultural and Ecological Research Unit, Indian Statistical Institute, 815301, Giridih, Jharkhand, India.
Biological trace element research
|August 23, 2025
概括
茶叶中的潜在有毒元素 (PTEs) 是全球性的健康问题. 这项研究发现北孟加拉的一些茶叶中的 (Pb) 含量超过了限制,这表明注中PTE的潜在消费者风险.
科学领域:
- 环境科学
- 食品安全问题
- 毒理学
背景情况:
- 茶是一种全球消费的饮料,
- 茶叶中存在潜在的有毒元素 (PTEs) 是一个严重的全球性问题.
- 了解PTE的生物可用性和从土壤转移到茶叶灌注对于公众健康至关重要.
研究的目的:
- 评估茶叶土壤中PTE的生物可用性及其转移到茶叶和灌注中.
- 评估印度北孟加拉州茶样中与PTE污染相关的潜在健康风险.
- 确定影响PTE生物可用性的因素,并制定风险减轻策略.
主要方法:
- 分析来自北孟加拉四个不同种植区的100个茶样.
- 在土壤,叶子和灌注中量化PTE (Cr,Ni,Cu,Zn,Pb).
- 应用自组织地图,Sobol灵敏度分析和随机森林算法来解释数据.
- 使用FIAM模型计算危险系数 (HQ),使用SAMOE模型计算致癌风险.
主要成果:
- 区域1 (北迪纳吉普尔) 的PTE从叶子转移到输液的比率最高,Pb超过了允许的限制.
- 茶叶中的PTE污染水平从1区下降到4区.
- 土壤pH和有机碳含量与生物可用PTE有相反的关系.
- 超过0. 5的Cr,Ni和Pb危险系数表明潜在的消费者风险,而致癌风险是可以忽略不计的.
结论:
- 在某些地区饮用茶叶可能会对健康造成危害,因为茶叶中含有.
- 土壤特性显著影响PTE的生物可用性和转移到茶中.
- 这些发现可以为确定PTE的耐受性限制提供信息,以确保茶叶的安全性.
相关概念视频
Mutagenicity and Carcinogenicity
2.0K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
Toxicokinetics: Overview
314
Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
314
Toxicity Testing in Animals
204
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
204
Pharmaceutical Poisoning: Potential Scenarios
116
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
116
Hazard Ratio
756
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
756


